Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
409 stopped studies mapped to Mature B-Cell Non-Hodgkin Lymphoma and descendants · 88% state a reason
Over the 409 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT00088881 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients… | Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02595242 | Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma | Phase 1 | withdrawn | Nov 3, 2015 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | not stated | Not stated |
| NCT02623920 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory…(S-BR) | Phase 2 | withdrawn | Dec 8, 2015 | University of Arizona | Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study… | Enrollment / accrual |
| NCT01282476 | Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | terminated | Jan 25, 2011 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
| NCT00645359 | Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large…(dMRI) | — | terminated | Mar 27, 2008 | University of Michigan Rogel Cancer Center | Insufficient resources to evaluate pilot, second to shift in research priorities | Other (stated, no rule matched) |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | Phase 2 | terminated | Aug 2, 2010 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT02285244 | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | withdrawn | Nov 6, 2014 | James Blachly | Decision made by the Principal Investigator | Investigator |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or…(VISMOLY) | Phase 2 | terminated | Sep 18, 2013 | The Lymphoma Academic Research Organisation | lack of efficacy | Efficacy / futility |
| NCT01389076 | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated,… | Phase 2 | terminated | Jul 7, 2011 | University of Michigan Rogel Cancer Center | Bexxar isn't being produced by the manufacturer as of Feb. 2014 | Drug supply |
| NCT02439138 | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in… | Phase 2 | terminated | May 8, 2015 | Dana-Farber Cancer Institute | Safety issues from trials in CLL | Safety / toxicity |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | Phase 2 | terminated | Mar 13, 2014 | University of Rochester | Lack of accrual | Enrollment / accrual |
| NCT00978432 | Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | terminated | Sep 17, 2009 | Anne Beaven, MD | The toxicity seemed to outweigh the benefit. | Safety / toxicity |
| NCT02653989 | Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Jan 13, 2016 | Medivation, Inc. | not stated | Not stated |
| NCT01423539 | A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed… | Phase 2 | withdrawn | Aug 26, 2011 | Genentech, Inc. | The NAVIGATE study has been terminated due to non-safety related reasons. | Safety / toxicity |
| NCT01609036 | An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular… | — | terminated | May 31, 2012 | Hoffmann-La Roche | not stated | Not stated |
| NCT01724294 | An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP… | — | terminated | Nov 9, 2012 | Hoffmann-La Roche | not stated | Not stated |
| NCT01144403 | A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients… | Phase 2 | terminated | Jun 15, 2010 | Hoffmann-La Roche | not stated | Not stated |
| NCT01121757 | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone… | Phase 2 | terminated | May 12, 2010 | Duke University | The study closed temporarily in February 2012 pending analysis of samples collected. In October,… | Other (stated, no rule matched) |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT02640833 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic… | Phase 1 | withdrawn | Dec 29, 2015 | AbbVie | Study Stopped | Other (stated, no rule matched) |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | Phase 1 | terminated | Mar 2, 2010 | Steven P. Treon, MD, PhD | Safety concerns (IgM Flare) | Safety / toxicity |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Jan 28, 2014 | Ångstrom Pharmaceuticals | Slow enrollment | Enrollment / accrual |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom… | Phase 2 | terminated | Feb 20, 2012 | Roswell Park Cancer Institute | funding was withdrawn | Funding |
| NCT02735876 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus… | Phase 3 | withdrawn | Apr 13, 2016 | Acerta Pharma BV | not stated | Not stated |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Sep 2, 2005 | Dana-Farber Cancer Institute | Toxicity | Safety / toxicity |
| NCT01578343 | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma(ZOLINZA) | Phase 2 | terminated | Apr 16, 2012 | Samsung Medical Center | we collected data of a total of 19 patients for an interim analysis. but there are less than 7… | Efficacy / futility |
| NCT00836173 | Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate,… | Phase 2 | withdrawn | Feb 4, 2009 | Loyola University | Gallium is no longer available for the conduct of this study. | Other (stated, no rule matched) |
| NCT02054559 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL(ASPIRE) | Phase 3 | withdrawn | Feb 4, 2014 | Asan Medical Center | No consensus among trial centers regarding protocol | Other (stated, no rule matched) |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | Phase 2 | terminated | Jun 15, 2006 | Asan Medical Center | poor accrual and response less than expected on interim analysis | Efficacy / futility |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma…(VEIL) | Phase 2 | terminated | Dec 28, 2011 | Peter MacCallum Cancer Centre, Australia | Poor recruitment rate | Enrollment / accrual |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects… | Phase 2 | terminated | Feb 24, 2009 | Januario Castro, M.D. | drug supply became unavailable | Drug supply |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | Phase 2 | terminated | Jul 20, 2009 | Januario Castro, M.D. | drug supply was no longer available | Drug supply |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Dec 18, 2007 | Dana-Farber Cancer Institute | Slow accrual led to early study termination. | Enrollment / accrual |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 10, 2009 | Georgetown University | Unable to accrue patients due to change in standard CLL therapy | Enrollment / accrual |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent… | Phase 1 | terminated | Oct 2, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell… | Phase 1 | terminated | Jan 11, 2010 | Case Comprehensive Cancer Center | Extreme toxicity in Phase I, study did not proceed to Phase II | Safety / toxicity |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell… | Phase 1 | terminated | Feb 26, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic… | Phase 1 | terminated | May 19, 2010 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT02258555 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With… | Phase 1 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell… | Phase 2 | withdrawn | Dec 20, 2010 | UNC Lineberger Comprehensive Cancer Center | No patients enrolled and funding has been withdrawn. | Enrollment / accrual |
| NCT01180569 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Aug 12, 2010 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Mar 30, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | terminated | Dec 22, 2011 | Duke University | Low accrual due to the approval of new drugs for use in Mantle cell lymphoma. | Enrollment / accrual |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Sep 27, 2004 | GlaxoSmithKline | Acquired asset | Other (stated, no rule matched) |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab… | Phase 3 | withdrawn | Apr 27, 2006 | GlaxoSmithKline | This study has been cancelled prior to enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 28, 2017source: clinicaltrials